Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I-II therapeutic vaccination clinical trial in patients with chronic hepatitis C by administration of autologous dendritic cells transduced with an adenoviral vector encoding NS3 protein

Proposed period of release:
08/04/2011 to 31/12/2013

Name of the Institute(s) or Company(ies)
ClĂ­nica Universidad de Navarra, ;

3. Is the same GMO release planned elsewhere in the Community?
Not known

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
AdNS3 is a recombinant defective adenovirus derived form human adenovirus type 5

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Human adenovirus type 5MastadenovirusHuman adenovirus type 5Type C adenovirus

European Commission administrative information

Consent given by the Member State Competent Authority:
01/07/2011 00:00:00